A Tiny Upstart Takes Aim at Robotic Surgery
Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX) Senhance. Senhance is a robotic system that assists surgeons performing laparoscopic surgeries. It offers advantages, including haptic feedback, that could differentiate it from Intuitive Surgical's da Vinci system. Will TransEnterix carve out a meaningful slice of this fast-growing market?
Intuitive Surgical's ground-breaking da Vinci systems are reshaping laparoscopic surgery.
IMAGE SOURCE: TRANSENTERIX.
Source: Fool.com
Intuitive Surgical Inc Aktie
410,85 €
-1,73 %
Die Community liebt Intuitive Surgical Inc: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Trotz eines Kursziels von 397 €, das unter 410.85 € liegt, ergibt sich für Intuitive Surgical Inc ein negatives Potenzial von -3.37%.
